2023
Deucravacitinib: A Novel TYK2 Inhibitor for the Treatment of Moderate-to-Severe Psoriasis
Kingston P, Blauvelt A, Strober B, Armstrong A. Deucravacitinib: A Novel TYK2 Inhibitor for the Treatment of Moderate-to-Severe Psoriasis. Journal Of Psoriasis And Psoriatic Arthritis 2023, 8: 156-165. PMID: 38188537, PMCID: PMC10768812, DOI: 10.1177/24755303231201336.Peer-Reviewed Original ResearchSevere plaque psoriasisTreatment of psoriasisPlaque psoriasisMechanism of actionLong-term extension studyNovel oral medicationsOral PDE4 inhibitorPalms/solesAcceptable safety profileHigh-risk patientsTreatment of adultsWeeks of treatmentTreatment of ModeratePivotal clinical studiesType I interferonPASI 75Tuberculosis evaluationSevere psoriasisIL-23Oral medicationsIL-12Blood testsSafety profilePsoriasis pathogenesisTriglyceride levels
2018
Social determinants of tuberculosis evaluation among household contacts: a secondary analysis
Shelby T, Meyer AJ, Ochom E, Turimumahoro P, Babirye D, Katamba A, Davis JL, Armstrong-Hough M. Social determinants of tuberculosis evaluation among household contacts: a secondary analysis. Public Health Action 2018, 8: 118-123. PMID: 30271727, PMCID: PMC6147061, DOI: 10.5588/pha.18.0025.Peer-Reviewed Original ResearchTB evaluationHousehold contactsContact investigationSocial determinantsHousehold contact investigationCross-sectional studyTuberculosis evaluationTB patientsPrimary level educationTuberculosis unitSputum collectionControl armIndividual symptomsSecondary analysisLow incomeSpecific mechanismsSocio-economic determinantsMedian incomeHead of householdFurther researchSocio-economic factorsPatientsDeterminantsClinicEvaluation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply